Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

被引：47
|
作者：
Lv, Meng [1 ]
Huang, Xiao-Jun [1 ]
机构：
[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷
基金：
中国国家自然科学基金;
关键词：
China; Allo-HSCT; Haploidentical; Relapse; GVHD; Elderly patients; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; RISK ACUTE-LEUKEMIA; ACUTE GVHD; ANTITHYMOCYTE GLOBULIN; MYCOPHENOLATE-MOFETIL; CLINICAL-OUTCOMES; T-CELLS; BLOOD;
D O I：
10.1186/1756-8722-5-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Fighting Misinformation: Where Are We and Where to Go?
    Nguyen, Huyen
    Ogbadu-Oladapo, Lydia
    Ali, Irhamni
    Chen, Haihua
    Chen, Jiangping
    Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 2023, 13971 LNCS : 371 - 394
  • [42] Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?
    van der Stoep, M. Y. Eileen C.
    Oostenbrink, Lisa V. E.
    Bredius, Robbert G. M.
    Moes, Dirk Jan A. R.
    Guchelaar, Henk-Jan
    Zwaveling, Juliette
    Lankester, Arjan C.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Transplantation tolerance: the big picture. Where do we stand, where should we go?
    Waldmann, H.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 189 (02): : 135 - 137
  • [44] LASERS: Where we began, where we have gone, where we are now. Where will we go?
    Reinisch, Lou
    LASERS IN SURGERY AND MEDICINE, 2023, 55 (10) : 861 - 861
  • [45] Haematopoietic Stem Cell Transplantation in Autoimmune Diseases Where are We Today?
    Henes, J. C.
    Wirths, S.
    AKTUELLE RHEUMATOLOGIE, 2016, 41 (02) : 152 - 156
  • [46] TRANSPLANTATION AND STEM CELL RESEARCH IN MOVEMENT DISORDERS - WHERE ARE WE NOW?
    Barker, R. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 1 - 1
  • [47] Allogeneic hematopoietic stem cell transplantation
    Kai, S
    Hara, T
    THERAPEUTIC APHERESIS AND DIALYSIS, 2003, 7 (03) : 285 - 291
  • [48] Allogeneic hematopoietic stem cell transplantation
    Faul, C.
    ONKOLOGIE, 2012, 35 : 112 - 112
  • [49] Genes and hypertension: Where we are and where we should go
    Hamet, P
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1999, 21 (5-6) : 947 - 960
  • [50] The working alliance: Where are we and where should we go?
    Castonguay, Louis G.
    Constantino, Michael J.
    Holtforth, Martin Grosse
    PSYCHOTHERAPY, 2006, 43 (03) : 271 - 279
12345